US FDA approves Takeda’s Livtencity to treat people with post-transplant Cytomegalovirus infection Read more
Covaxin shows 50 per cent effectiveness against symptomatic COVID in real-world assessment: Lancet study Read more
New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust efficacy and long-term prevention Read more